Cardiac Amyloidosis Clinical Trials
12 recruiting trials for Cardiac Amyloidosis. Eligibility criteria explained in plain English.
TrialFinderData lists 12 Cardiac Amyloidosis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by University Hospital, Essen (2), University of Leipzig (1), Helse Møre og Romsdal HF (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Routine diagnostics (other, 1 trial), followed by Routine treatment, 18F-92/AV45/TPZA/FT8, 11CPIB.
Track Cardiac Amyloidosis trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease
This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using...
Cardiac Amyloidosis Registry of University Hospital Leipzig
This is a clinical registry of patients with cardiac amyloidosis being treated at University Hospital Leipzig. The aim of the registry is to collect detailed information about...
ATTR Cardiac Amyloidosis in a Selected Population
Patients operated for carpal tunnel syndrome (CTS) at Ålesund Hospital (200 patients) will have a biopsy to diagnose ATTR amyloidosis. Patients with positive biopsy will be...
Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis
Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac...
Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance...
What is this study about? This research is focused on improving the care for people with rare heart muscle diseases, known as rare cardiomyopathies. These are uncommon conditions...
Cardiovascular Multimodality Imaging Study
Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis. There is increased risk for cardiovascular...
MECKI-Amyloidosis: Assessment of the Exercise Capacity and Prognosis of Patients with Cardiac Amyloidosis
This study aims to advance the understanding of cardiac amyloidosis, its effects on exercise capacity, and its prognostic implications. By conducting a systematic investigation...
Echocardiographic Characterization of Cardiac Amyloidosis
This is a mono-center observational ambispective study in which patients with cardiac amyloidosis evaluated at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS...
Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
The aim of the study is to evaluate coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and proportion of overt microvascular disease, defined as depressed...
Pan-Amyloid PET/CT in Various Amyloid-Related Disease
To evaluate the potential usefulness of 18F-92/AV45/TPZA/FT8, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions...
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Primary objective: To identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course of the illness, at a time when disease modifying therapies are...
A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation
The purpose of this study is to deploy and evaluate informational AI-Echo algorithms that assist echo clinicians in interpreting core echocardiographic parameters (e.g., LV/RV...
Explore Other Conditions
Frequently Asked Questions
There are currently 12 clinical trials for Cardiac Amyloidosis, with 12 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Cardiac Amyloidosis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Cardiac Amyloidosis, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.